Sam­sung Bioepis launch­es a Rem­i­cade knock­off at a 35% dis­count; FDA OK’s a self-ad­min­is­tered ver­sion of Benlysta

→ The South Ko­re­an biosim­i­lar play­er Sam­sung Bioepis has launched a copy­cat of Rem­i­cade on the US mar­ket at a 35% dis­count to J&J’s list price for that ther­a­py. Rem­i­cade is J&J’s top earn­er, and the phar­ma gi­ant has filed suit to try and stop Sam­sung’s ri­val for be­ing in­tro­duced. There’s been con­sid­er­able spec­u­la­tion on how gener­ic ver­sions of bi­o­log­ics could im­pact pric­ing.

→ The FDA ap­proved a sub­cu­ta­neous for­mu­la­tion of Benlysta for lu­pus, mak­ing it pos­si­ble for pa­tients to switch from an IV ver­sion of the GSK drug to a self-ad­min­is­tered shot.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER